Fair Value Measurements (Details) - Recurring - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2016	Dec. 31, 2015
Financial instruments measured at fair value on a recurring basis
Warrant consideration	[1]	$ 4,680	$ 6,000
Total		196,503	178,320
Tax amortization benefit contingency
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[2]	163,498	149,620
Deferred acquisition payment
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[3]	28,325	22,700
Significant other observable inputs (Level 2)
Financial instruments measured at fair value on a recurring basis
Warrant consideration	[1]	4,680	6,000
Total		4,680	6,000
Significant unobservable inputs (Level 3)
Financial instruments measured at fair value on a recurring basis
Total		191,823	172,320
Significant unobservable inputs (Level 3) | Tax amortization benefit contingency
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[2]	$ 163,498	149,620
Tax effect rate		37.00%
Significant unobservable inputs (Level 3) | Deferred acquisition payment
Financial instruments measured at fair value on a recurring basis
Contingent consideration	[3]	$ 28,325	$ 22,700

[1] This liability relates to warrants to purchase the Company's common stock and future obligations to deliver additional such warrants in relation to the Business Combination. The inputs used in the fair value measurement were directly observable quoted prices for identical assets in an inactive market.

[2] The fair value of the tax amortization benefit contingency is measured using an income approach based on the Company's best estimate of the undiscounted cash payments to be made, tax effected at 37% and discounted to present value utilizing an appropriate market discount rate. The valuation technique used did not change during the nine months ended September 30, 2016.

[3] The fair value of the deferred acquisition payment is measured using a Black-Scholes option pricing model and based on the Company's best estimate of the Company's average Business EBITDA, as defined in the Purchase Agreement, over the two year period from January 1, 2016 to December 31, 2017. The valuation technique used did not change during the nine months ended September 30, 2016.